[{"NetIncomeLoss_1_Q2_USD":-122428000.0,"AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0_Q2_USD":247000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":91060000.0,"RestrictedCashCurrent_0_Q2_USD":10000000.0,"InventoryFinishedGoods_0_Q2_USD":5626000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":232000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-223670000.0,"AssetsCurrent_0_Q2_USD":949492000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-511000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":664347000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":106668000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":53410000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":8292032.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":8500068.0,"AvailableForSaleSecurities_0_Q2_USD":941373000.0,"CommonStockSharesIssued_0_Q2_shares":67764950.0,"Assets_0_Q2_USD":1512444000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-457000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":176000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":38619000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":9002000.0,"CommonStockSharesAuthorized_0_Q2_shares":250000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":186370000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":86975000.0,"EquitySecuritiesFvNiGainLoss_2_Q2_USD":-51665000.0,"EquitySecuritiesFvNiGainLoss_1_Q2_USD":-31046000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"AvailableForSaleSecuritiesAmortizedCost_0_Q2_USD":941388000.0,"EarningsPerShareBasic_2_Q2_USD":-3.84,"EarningsPerShareBasic_1_Q2_USD":-1.81,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2_Q2_USD":406614000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":67356443.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":67607752.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-862000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-67000.0,"AccountsReceivableNetCurrent_0_Q2_USD":24720000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":842000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":463000.0,"CommonStockValue_0_Q2_USD":68000.0,"OperatingIncomeLoss_2_Q2_USD":-189345000.0,"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0_Q2_USD":128031000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":82000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":25277000.0,"IncreaseDecreaseInInventories_2_Q2_USD":2174000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-259026000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-122252000.0,"OtherAssetsNoncurrent_0_Q2_USD":12668000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":290875000.0,"Liabilities_0_Q2_USD":540273000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2_Q2_USD":25503000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-275000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":73000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":6488000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":113205000.0,"OperatingIncomeLoss_1_Q2_USD":-82776000.0,"InventoryNet_0_Q2_USD":15083000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":27099000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-224702000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2_Q2_USD":70548000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":67356443.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":67607752.0,"InventoryWorkInProcess_0_Q2_USD":9457000.0,"LiabilitiesCurrent_0_Q2_USD":127067000.0,"AccountsPayableCurrent_0_Q2_USD":21790000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":63933000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_Q2_USD":-323000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":26964000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":130950000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_2_Q2_USD":-182000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_1_Q2_USD":103000.0,"AdditionalPaidInCapital_0_Q2_USD":2850016000.0,"AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0_Q2_USD":-15000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":302876000.0,"DeferredIncomeTaxLiabilitiesNet_0_Q2_USD":33306000.0,"AvailableForSaleSecuritiesGrossRealizedGainLossNet_2_Q2_USD":0.0,"AvailableForSaleSecuritiesGrossRealizedGainLossNet_1_Q2_USD":0.0,"ProceedsFromPaymentsForOtherFinancingActivities_2_Q2_USD":-226000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":104568000.0,"NetIncomeLoss_2_Q2_USD":-258569000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":51319000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-121965000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-257727000.0,"Goodwill_0_Q2_USD":44406000.0,"InvestmentIncomeInterest_2_Q2_USD":1080000.0,"InvestmentIncomeInterest_1_Q2_USD":441000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":67000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":3912000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":1512444000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":41545000.0,"PreferredStockSharesAuthorized_0_Q2_shares":25000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":51440000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":27142000.0,"OperatingExpenses_2_Q2_USD":375715000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":554881000.0,"OperatingExpenses_1_Q2_USD":169751000.0,"StockholdersEquity_0_Q2_USD":972171000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":36485000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":-2511000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1878145000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-423418000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":1669000.0,"CommonStockSharesOutstanding_0_Q2_shares":67764950.0,"EarningsPerShareDiluted_2_Q2_USD":-3.84,"EarningsPerShareDiluted_1_Q2_USD":-1.81,"RestrictedCashNoncurrent_0_Q2_USD":2001000.0,"InvestmentsFairValueDisclosure_0_Q2_USD":1044464000.0,"ProfitLoss_2_Q2_USD":-258569000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":260723000.0,"Ticker":"RARE","CIK":"1515673","name":"ULTRAGENYX PHARMACEUTICAL INC.","OfficialName":"Ultragenyx Pharmaceutical Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"5418950849.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210803"}]